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It has been extremely difficult to elicit broadly cross-reactive neutralizing antibodies (Nabs) against human immunodefi-
ciency virus type 1 (HIV-1). In this study, we compared the immunogenic properties of the wild-type and variable loop-deleted
HIV-1 envelope glycoproteins. Mice were immunized with recombinant vaccinia viruses expressing either the wild-type or the
variable loop-deleted (V1–2, V3, V4, and V1–3) HIV-1DH12 gp160s. The animals were subsequently boosted with respective
recombinant gp120s. All envelope constructs elicited similar levels of gp120-binding antibodies when analyzed by enzyme-
linked immunosorbent assay (ELISA). However, the highest neutralizing activity was observed in sera from animals
immunized with the wild-type envelope protein, followed by those immunized with V4 and V1–2. No neutralizing activity
was detected in sera from animals immunized with V3 or V1–3. To identify immunogenic epitopes, ELISA was performed
with overlapping 15-mer peptides that cover the entire length of gp120. For the wild-type gp120, the immunogenic epitopes
mapped primarily to the variable loops V1–2 and to the conserved regions C1 and C5. When they were plotted onto known
coordinates of gp120 core crystal structure, the epitopes in the conserved regions mapped predominantly to the inner
domain of the protein. By immunizing with variable loop-deleted envelopes, the immune responses could be redirected to
other regions of the protein. However, the newly targeted epitopes were neither on the exposed surface of the protein nor
on the receptor binding regions. Interestingly, the removal of the V3 loop resulted in loss of immunoreactivity for both V3 and
V1/V2 loops, suggesting structural interaction between the two regions. Our results suggest that obtaining broadly reactive
Nabs may not be achieved simply by deleting the variable loops of gp120. However, the observation that the immunemodifying the antigenic properties of HIV-1 envelope glyco
INTRODUCTION
It is estimated that there are now over 40 million
people infected with human immunodeficiency virus type
1 (HIV-1) worldwide (UNAIDS/WHO Report, 2001). Al-
though it has been nearly two decades since HIV-1 was
identified as the etiologic agent of acquired immunode-
ficiency syndrome (AIDS), there is still no vaccine against
the virus. With high cost and serious side effects of
anti-retroviral therapy and the increase in viral resistance
against anti-HIV-1 drugs, there is a great urgency for
developing a vaccine against the virus.
One of the biggest obstacles in developing an effec-
tive AIDS vaccine is the extreme difficulty in eliciting
neutralizing antibodies (Nabs) that are broadly reactive
against many HIV-1 isolates that exist. The difficulty in
eliciting Nabs against the virus comes from three major
factors. First, the antigenic structure of the viral surface
envelope glycoprotein, gp120, is highly variable from
1 To whom correspondence and reprint requests should be ad-
dressed at Case Western Reserve University School of Medicine,
Department of Medicine, Division of Infectious Disease, 10900 Euclid. © 2002 Elsevier Science (USA)
isolate to isolate, with five hypervariable regions (V1–V5).
Nabs directed against these variable regions are strain-
specific, with very little cross-reactivity between clinical
isolates. Second, gp120 is extensively glycosylated.
There are 23 to 24 asparagine (N)-linked glycosylation
sites and the carbohydrate moieties account for approx-
imately one-half of the protein’s entire mass. In addition
to being important for the functional and structural integ-
rity of the protein (see Ogert et al., 2001 and references
therein), these sugar residues affect the antigenicity and
immunogenicity of the protein (Back et al., 1994; Davis et
al., 1990; Huang et al., 1997; Papandreou and Fenouillet,
1998; Reitter et al., 1998; Schonning et al., 1996). The
carbohydrate structures, in effect, shield the virus from
Nabs. Finally, the conserved regions of the protein that
bind cellular receptors CD4 and coreceptors (viz. CXCR4
or CCR5) are obscured by the variable loops. The CD4-
binding site lies in a deep pocket partly covered by the
variable loops V1 and V2 (Kwong et al., 1998; Wyatt et al.,
1998). The coreceptor-binding site is exposed only tran-
siently following the conformational change that occurs
after binding CD4 (Wyatt et al., 1995). Consequently, theresponses could be redirected by altering the protein co
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The crystal structure of the core domain of gp120,
along with the two amino-terminal domains of CD4 and
Fab fragment of a monoclonal antibody 17b that binds
CD4-induced domain, has been solved (Kwong et al.,
1998). Despite the fact that the crystallized protein has
multiple missing segments of gp120 (viz. 52 and 19
amino acids at the amino- and carboxyl-terminus, re-
spectively, and the variable loops V1/V2 and V3), the
overall structural information from the crystal largely
agree with biochemical, immunological, and genetic
data available from other studies (Helseth et al., 1991;
Leonard et al., 1990; Moore and Sodroski, 1996; Ol-
shevsky et al., 1990). The poor immunogenic property of
gp120 in eliciting broadly reactive Nabs against the virus
is readily apparent from the analyses of the crystal struc-
ture of gp120 core. Based on the three-dimensional
model derived from the crystal structure, a significant
fraction of the exposed surface of the trimeric envelope
glycoprotein on the virion is occupied by carbohydrate
residues and the hypervariable regions (Wyatt et al.,
1998). Thus, to elicit Nabs that have broad cross-reactiv-
ity against a large number of genetically diverse HIV-1
isolates, a vaccine candidate has to be designed so that
the conserved regions of gp120 are exposed as much as
possible.
A number of strategies have been proposed or are
being explored to elicit broadly reactive Nabs, including
the use of fusion intermediates (LaCasse et al., 1999),
CD4-independent envelope glycoproteins (Hoffman et
al., 1999), glycosylation site mutants (Quinones-Kochs et
al., 2002; Reitter et al., 1998), and variable loop-deleted
envelope proteins (Barnett et al., 2001; Johnson et al.,
2002; Lu et al., 1998; Wyatt et al., 1993). The rationale
behind these approaches is to expose conserved
epitopes of the protein (viz. CD4- or coreceptor-binding
sites) that should be common to many HIV-1 isolates by
either eliminating shields (i.e., carbohydrates or variable
loops) or by capturing various transitional states of the
envelope. In this study, the feasibility of using variable
loop-deleted envelope glycoproteins as vaccine candi-
dates against HIV-1 was evaluated. The specific goals of
the study are (1) to identify immunogenic epitopes in the
wild-type envelope glycoprotein of a dual tropic HIV-1
isolate (DH12); (2) to determine whether it is possible to
redirect antibody responses from variable to conserved
regions of the protein by removing the variable loops;
and (3) to compare the potency and breadth of neutral-
izing activity of antisera elicited by the wild-type and
mutant envelope constructs.
RESULTS
Expression of HIV-1 envelope glycoprotein
To characterize humoral immune response elicited by
variable loop-deleted HIV-1 envelope glycoproteins, re-
combinant vaccinia viruses expressing gp160 and gp120
were generated. The recombinant viruses expressing
the wild-type proteins have previously been described
(Cho et al., 2000, 2001; Lee et al., 2000) and the variable
loops V1–2, V3, V4, and V1–3 were deleted, as illustrated
in Fig. 1. The viruses encoding gp160 express the protein
under the control of vaccinia virus immediate-early pro-
moter P7.5. In contrast, transcription of gp120 is con-
trolled by T7 promoter. Thus, gp120 is expressed when
cells are coinfected with gp120-encoding viruses and
another recombinant vaccinia virus expressing T7 RNA
polymerase (vTF7-3) (Fuerst et al., 1986). Gp120 is tagged
with six histidine residues at the carboxyl-terminus to
facilitate protein purification. During the variable loop
deletion procedure, restriction sites BamHI, EcoRI, and
XbaI were introduced at the V1–2, V3, and V4 loops,
respectively. As a result, the variable loops were re-
placed with dipeptides Glycine-Serine, Glutamic acid-
Phenylalanine, and Proline-Glycine, respectively.
Expression of envelope glycoproteins by the recombi-
nant vaccinia viruses is shown in Fig. 2. All of the mutant
gp120s were expressed and secreted into the culture
medium as efficiently as the wild-type gp120 (Fig. 2A). As
expected, V1–3 gp120 exhibited the greatest increase
in mobility, followed by V1–2. Only a slight increase in
mobility was observed for V3 and V4. All gp120s
bound Ni-NTA resin, although mutant proteins exhibited
somewhat weaker affinity than the wild-type. As a result,
lower salt concentration was used during the purification
procedure. All of the gp160s were expressed efficiently
(Fig. 2B). The variable loop-deleted gp160s exhibited
similar changes in mobility as for corresponding gp120s.
Wild-type gp160 was processed efficiently as indicated
by the large amount of gp120 in culture medium. Among
the variable loop-deleted mutant proteins, only V1–2
was processed efficiently. While some processing was
observed for V3 and V4, no processing was observed
for V1–3. These results suggest that intact variable
loops V3 and V4 are important for maintaining correct
conformation of the protein necessary for protein pro-
cessing. Not unexpectedly, none of the mutant gp160
clones, including the V1–2 construct, exhibited any de-
tectable fusion activity (data not shown) using the highly
sensitive cell-to-cell fusion assay we previously de-
scribed (Lee et al., 1999).
Immunization and evaluation of antibody response
We have previously demonstrated that immunization of
macaques with recombinant vaccinia virus expressing
gp160, followed by boosting with purified recombinant
gp120, could elicit potent neutralizing antibodies that
protect vaccinated animals (Cho et al., 2001). A similar
prime-boost vaccine strategy was used (Table 1). Mice
were immunized with either the wild-type or the variable
loop-deleted envelope glycoprotein. The animals were
initially primed with recombinant vaccinia viruses ex-
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FIG. 1. Construction of variable loop-deleted HIV-1 envelope glycoprotein. (A) Schematic diagram of wild-type gp120 expression vector, pTM-
DHgp120H (Lee et al., 2000). The transcription of HIV-1DH12 gp120 is under the control of T7 promotor (PT7) and T7 terminator (TT7). The translation of
the protein is enhanced by the presence of internal ribosome entry site (IRES). The protein is tagged with six histidine residues (6His) at the
carboxyl-terminus to facilitate protein purification. The positions of endonuclease restriction sites PstI (P), NsiI (N), StuI (S), BglII (B), and XhoI (X) are
indicated. PCR-amplified fragments used to generate mutant constructs and the relative positions of the primers used for the PCR reaction are shown.
During the cloning procedure, restriction sequences for BamHI, EcoRI, and XbaI were introduced into the V1–2, V3, and V4 loops, resulting in insertion
of dipeptides GS, EF, and PG, respectively, between the cysteine residues at the base of the variable loops. (B) Primers used for the PCR reaction.
F- and R-env refer to forward and reverse primers at the 5 and 3 of gp120 gene, respectively. The coding sequences are indicated by bold phase,
the XhoI site is underlined, and six histidine residues are boxed in. The internal primers used to amplify either upstream (U) or downstream (D) PCR
fragments (relative to each variable loop) for generating V1–2, V3, and V4 gp120s are indicated. The restriction sites introduced into the primers
are underlined and the coding regions (up to the cystein residues) are indicated by bold phase. The nucleotide numbering is based on HIV-1DH12 strain.
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pressing gp160. For second and third immunizations on
4 and 11 weeks post-initial immunization, respectively,
mice were immunized with both the recombinant vac-
cinia viruses and the purified recombinant gp120s. For
the final boost on Week 17, mice were immunized with
gp120 only. As a negative control, one group of mice was
immunized with a recombinant vaccinia virus expressing
SIV gag-pol on weeks 0, 4, and 11, and with recombinant
p55 protein on Week 17. Expression of SIV gag-pol and
purification of p55 will be described in detail elsewhere
(Y. B. Kim, D. P. Han, and M. W. Cho, unpublished data).
Humoral immune response against HIV-1 envelope
glycoprotein was evaluated by enzyme-linked immu-
nosorbent assay (ELISA). An assay performed with sera
collected after the final immunization is shown in Fig. 3.
FIG. 3. Antibody response against gp120. Antisera from animals
immunized with either the wild-type or the variable loop-deleted mutant
envelope proteins were analyzed by ELISA. Wild-type gp120 from
HIV-1DH12 was used as antigen. The absorbance (at 450 nm) is shown
as a function of serum dilution factor. Antisera from animals immunized
with SIV gag-pol was used as a negative control. The final bleed,
obtained after the last boost, was used.
FIG. 2. Expression of the wild-type and variable loop-deleted gp120s
(A) and gp160s (B). Gp120 was expressed in HeLa cells by coinfection
with recombinant vaccinia viruses that encode various gp120s under
the control of T7 promoter and a second virus that expresses T7 RNA
polymerase (vTF7-3). Because these constructs lack gp41 region,
gp120 is secreted directly into cell-culture medium. In contrast, gp160
was expressed by infection with a single recombinant vaccinia virus
that encodes gp160 under the control of vaccinia P7.5 promoter. While
gp160 is found only in cell lysate (i.e., membrane-associated), most of
the processed gp120 is shed into culture medium. Envelope proteins
were detected by Western immunoblot using polyclonal rabbit anti-
gp160 antiserum.
TABLE 1
Vaccine Design and Immunization Schedule
Vaccine
No. of
mice 1 (Week 0) 2 (Week 4) 3 (Week 11) 4a (Week 17)
SIVgagpol 4 vvSIVgagpol vvSIVgagpol vvSIVgagpol SIV p55




V1–2 4 vvDHenvV1–2 vvDHenvV1–2 vvDHenvV1–2
gp120V1–2 gp120V1–2 gp120V1–2
V3 4 vvDHenvV3 vvDHenvV3 vvDHenvV3
gp120V3 gp120V3 gp120V3
V4 4b vvDHenvV4 vvDHenvV4 vvDHenvV4
gp120V4 gp120V4 gp120V4
V1–3 4 vvDHenvV1–3 vvDHenvV1–3 vvDHenvV1–3
gp120V1–3 gp120V1–3 gp120V1–3
Note. Recombinant proteins are indicated in bold.
a Administered with 50 g of QS-21 as adjuvant.
b One animal died during relocation to a new facility.
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The antibody response against gp120 was about the
same for all envelope-immunized vaccine groups with
endpoint titers of approximately 1:30,000. This repre-
sents approximately 10-fold higher titer compared to that
found in HIV-1-infected patients when measured under
the same assay condition. Envelope-specific antibody
was not detected in preimmune sera (data not shown) or
in animals immunized with SIV gag-pol (Fig. 3). Antibody
titers of sera collected after the third immunization were
similar to those collected after the final immunization for
all vaccine groups except for those immunized with V3
and V1–3, which were about threefold lower (data not
shown). This result suggests that V3- and V1–3-deleted
envelope glycoproteins might be slightly less immuno-
genic than the other envelope constructs. The animals
were not bled after the first and second immunization
because we normally do not detect or detect only low
levels of antigen-specific antibody response. Mice im-
munized with recombinant vaccinia virus expressing SIV
gag-pol and p55 protein mounted a strong antibody re-
sponse against SIV p55 as well as p27 and p17 (data not
shown).
Neutralization activity
To determine whether the variable loop-deleted enve-
lope constructs could elicit Nabs that are more potent
and/or have greater breadth in reactivity than those elic-
ited by the wild-type, neutralizing activity of sera col-
lected after the final immunization was evaluated. We
have recently described a rapid, highly sensitive neutral-
ization assay that uses -galactosidase-encoding mu-
rine leukemia virus (MuLV) pseudotyped with HIV-1
gp140 (Kim et al., 2001). Neutralizing activity of antisera
against MuLV pseudotyped with gp140 of HIV-1 isolates
DH12, Bal, AD8, 89.6, and RF is shown in Table 2. Against
DH12, which is the HIV-1 strain used to generate gp160
and gp120 immunogens, the group immunized with the
wild-type protein exhibited the highest neutralizing activ-
ity (1:16), followed by those immunized with V4 (1:8) and
V1–2 (1:4). No neutralizing activity was detected in
animals immunized with V3, V1–3, or SIV gag-pol.
None of the vaccine groups had any detectable neutral-
izing activity against other HIV-1 isolates, including the
group immunized with wild-type protein. The inability to
neutralize these viruses is not due to the inherently
resistant nature of pseudoviruses since they were neu-
tralized by broadly neutralizing monoclonal antibody IgG
b12 (Table 2). No neutralizing activity was detected in
prebleeds from any of the animals.
Characterization of immunogenic epitopes
Although the variable loop-deleted envelope glycopro-
teins we have generated were not able to elicit neutral-
izing antibodies that are either potent or broadly reactive,
understanding immunogenic properties of these anti-
gens in comparison to those of the wild-type protein
could facilitate design of a better immunogen in the
future. To identify epitopes that are immunogenic, ELISA
was performed against 93 gp120 peptides that are 15
amino acids in length and overlap by 10 amino acids
(Table 3). These peptides cover the entire length of
HIV-1DH12 gp120, except for the signal peptide. The anti-
body response against these peptides is shown in Fig. 4.
In animals immunized with the wild-type envelope glyco-
protein, 16 highly immunogenic epitopes (arbitrarily de-
fined as having A450 of greater than 1.0) were identified
(Fig. 4, top panel, and Table 3). These epitopes were
primarily located in the C1, V1/V2, and C5 regions of
gp120, which accounted for 75% of all immunogenic
epitopes. The immunogenic epitope identified in the V3
loop (peptide 56) contained the Gly-Pro-Gly-Arg se-
quence situated in the middle of the peptide. These
amino acids, located at the tip of the V3 loop, have been
previously shown to be important in eliciting isolate-
specific Nabs (Goudsmit et al., 1988; Javaherian et al.,
1990; McKeating et al., 1989; Palker et al., 1988; Rusche
et al., 1988). Although the adjacent peptides (nos. 55 and
57) also contained GPGR motif, they were not immuno-
reactive, suggesting the importance of proper geometry
of the motif in order for it to be antigenic. There are two
cautionary notes regarding the immunogenic epitopes
identified in this study. First, the epitopes we identified
represent only those that are linear and those that can be
folded into by 15 amino acid long peptides. Epitopes that
are discontinuous or those that require longer peptides
would not be identified. Second, since the peptides we
used overlap by 10 amino acids, we do not know whether
multiple immunoreactive peptides that are adjacent to
each other (i.e., peptides 12/13, 22/23/24, and 87/88)
represent multiple independent epitopes or a single
epitope that can be displayed by different peptides.
Antisera from the animals immunized with the variable
TABLE 2
Neutralization of HIV-1 gp140 Pseudoviruses With Immunized
Mice Seraa
Vaccine DH12 Bal AD8 89.6 RF
SIVgagpol — — — — —
W.T. 1:16 — — — —
V1–2 1:4 — — — —
V3 — — — — —
V4 1:8 — — — —
V1–3 — — — — —
IgG b12b 25 12.5 12.5 12.5 0.78
a Serum dilution required to yield 90% reduction of 50 IFU of gp140-
pseudotyped virus.
b Antibody concentration (g/ml) that yielded complete neutralization
of the pseudoviruses.
—, No neutralizing activity was detected at 1:4 dilution.
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loop-deleted envelopes were also examined. The results
are shown as A450 of wild-type subtracted from A450 of
mutants for each peptide (Fig. 4, bottom four panels).
Thus, the positive values represent greater immunoge-
nicity for the mutant envelopes, while the negative values
represent greater immunogenicity for the wild-type pro-
tein. Values close to zero represent little or no difference
between the wild-type and mutant proteins. As predicted,
sera from the animals immunized with V1–2 envelope
lost immunoreactivity against the V1–2 peptides. While
most peptides had similar immunoreactivity, six peptides
were significantly more immunogenic (arbitrarily defined
as the difference of greater than A450 of 1) compared to
the wild-type (peptides 47, 54, 55, 85, 86, and 92). Pep-
tides 54 and 55 are located in the V3 loop, while peptides
85 and 86 are located in the V5 region. Only two peptides
were from the conserved regions of gp120 (C2 and C5).
Also as expected, antisera from the animals immu-
nized with the V3 envelope lost immunoreactivity
against peptide 56. Surprisingly, immunoreactivity
against the V1–2 loop peptides was also reduced almost
as much as the V1–2 immunized group. This result
suggests that conformation of the V3 loop has a signifi-
cant influence on how the V1–2 loops are folded. Immu-
noreactivity against peptide 40 in the C2 region was also
lost. In contrast, immunoreactivity against three peptides
in C1 and C2 increased (7, 47, and 48). It is interesting
that immunoreactivity against peptide 47 was enhanced
by the removal of either V1–2 or V3 loops. Deletion of V4
loop reduced immunogenicity of peptides 6, 22, 30, and
61. In contrast, immunogenicity of peptides 11, 28, and to
a lesser degree peptides 10, 92, and 93, was increased.
The immunoreactivity pattern for the V1–3 group largely
resembled that for the V1–2 and V3 groups combined
(i.e., loss of reactivity against both V1–2 and V3 peptides).
In addition, reactivity toward peptide 87 was lost. In
contrast, reactivity toward several peptides in the C1 and
C5 increased (peptides 11, 14, and to a lesser degree 10,
92, and 93).
To visualize immunogenic epitopes in a three-dimen-
TABLE 3
List of Peptides Used for ELISA
Number Sequence Number Sequence Number Sequence
1 AEQLWVTVYYGVPVW 32 DRNITSYRLISCNTS 63 TLKRVVEKLREKFEN
2 VTVYYGVPVWKEANT 33 SYRLISCNTSTLTQA 64 VEKLREKFENKTIVF
3 GVPVWKEANTTLFCA 34 SCNTSTLTQACPKVS 65 EKFENKTIVFNKSSG
4 KEANTTLFCASDAKA 35 TLTQACPKVSFEPIP 66 KTIVFNKSSGGDPEI
5 TLFCASDAKAYDTEV 36 CPKVSFEPIPIHYCA 67 NKSSGGDPEIVMHSF
6 SDAKAYDTEVHNVWA 37 FEPIPIHYCAPAGFA 68 GDPEIVMHSFNCGGE
7 YDTEVHNVWATHACV 38 IHYCAPAGFAILKCK 69 VMHSFNCGGEFFYCN
8 HNVWATHACVPTDPN 39 PAGFAILKCKDKKFN 70 NCGGEFFYCNTKKLF
9 THACVPTDPNPQEIL 40 ILKCKDKKFNGTGPC 71 FFYCNTKKLFNSTWN
10 PTDPNPQEILLENVT 41 DKKFNGTGPCTNVST 72 TKKLFNSTWNGTEGS
11 PQEILLENVTEDFNM 42 GTGPCTNVSTVQCTH 73 NSTWNGTEGSYNIEG
12 LENVTEDFNMWKNNM 43 TNVSTVQCTHGIRPV 74 GTEGSYNIEGNDTIT
13 EDFNMWKNNMVEQMH 44 VQCTHGIRPVVSTQL 75 YNIEGNDTITLPCRI
14 WKNNMVEQMHEDIIS 45 GIRPVVSTQLLLNGS 76 NDTITLPCRIKQIIN
15 VEQMHEDIISLWDQS 46 VSTQLLLNGSLAEEE 77 LPCRIKQIINMWQEV
16 EDIISLWDQSLKPCV 47 LLNGSLAEEEVVIRS 78 KQIINMWQEVGKAMY
17 LWDQSLKPCVKLTPL 48 LAEEEVVIRSSNFTD 79 MWQEVGKAMYAPPIS
18 LKPCVKLTPLCVTLH 49 VVIRSSNFTDNAKII 80 GKAMYAPPISGQIWC
19 KLTPLCVTLHCTDLK 50 SNFTDNAKIIIVQLN 81 APPISGQIWCSSNIT
20 CVTLHCTDLKNGTNL 51 NAKIIIVQLNETVEI 82 GQIWCSSNITGLLLT
21 CTDLKNGTNLKNGTK 52 IVQLNETVEINCTRP 83 SSNITGLLLTRDGGK
22 NGTNLKNGTKIIGKS 53 ETVEINCTRPNNNTR 84 GLLLTRDGGKNSSTE
23 KNGTKIIGKSMRGEI 54 NCTRPNNNTRKGITL 85 RDGGKNSSTEIFRPG
24 IIGKSMRGEIKNCSF 55 NNNTRKGITLGPGRV 86 NSSTEIFRPGGGDMR
25 MRGEIKNCSFNVTKN 56 KGITLGPGRVFYTTG 87 IFRPGGGDMRDNWRS
26 KNCSFNVTKNIIDKV 57 GPGRVFYTTGEIVGD 88 GGDMRDNWRSELYKY
27 NVTKNIIDKVKKEYA 58 FYTTGEIVGDIRKAH 89 DNWRSELYKYKVVRV
28 IIDKVKKEYALFYRH 59 EIVGDIRKAHCNISK 90 ELYKYKVVRVEPLGI
29 KKEYALFYRHDVVPI 60 IRKAHCNISKVKWHN 91 KVVRVEPLGIAPTKA
30 LFYRHDVVPIDRNIT 61 CNISKVKWHNTLKRV 92 EPLGIAPTKAKRRVV
31 DVVPIDRNITSYRLI 62 VKWHNTLKRVVEKLR 93 APTKAKRRVVQREKR
Note. Immunoreactive peptides are boxed (see Fig. 4). Peptides that include the variable regions are shaded: V1/V2: 19–33; V3: 53–60; V4: 70–76;
V5: 84–86.
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sional model of gp120, we plotted the immunoreactive
peptides onto the corresponding coordinates of gp120
crystal structure solved by Kwong et al. (1998) (Fig. 5).
The peptides that reacted strongly to antisera from the
animals immunized with the wild-type envelope glyco-
protein are shown in Fig. 5A. Because the crystallized
gp120 core has multiple missing segments of gp120 (viz.
52 and 19 amino acids at the amino- and carboxyl-
terminus, respectively, and the variable loops V1/V2 and
V3), not all immunogenic epitopes could be displayed on
the crystal structure. Only those indicated by asterisks in
Fig. 4 are shown. By-and-large, most of the immunogenic
peptides mapped to the inner domain of gp120 (peptides
12, 13, and 15 in red; peptide 40 in blue; peptides 87 and
88 in cyan; and peptide 91 in magenta), which has been
referred to as “nonneutralizing face” (Wyatt et al., 1998).
Only peptides 46 in C2 (yellow) and 61 in C3 (green) (not
including the immunogenic peptides in the variable
loops) were situated in the outer domain of the protein.
No peptides mapped to regions that are highly glycosy-
FIG. 4. Characterization of immunogenic epitopes by peptide ELISA. The final bleed was analyzed by ELISA against the peptides listed in Table
3. The peptides are labeled on the bottom of the graph (1–93). On the top, the absorbance (at 450 nm) for the antisera from the animals immunized
with the wild-type envelope is shown for each peptide. For the variable loop-deleted envelopes (bottom four panels), the results are shown as A450
of wild-type subtracted from A450 of mutants for each peptide. Approximate locations of the conserved (C1–5) and variable (V1–5) regions are indicated.
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FIG. 5. Three-dimensional visualization of immunogenic epitopes. Immunoreactive peptides identified in Fig. 4 (marked by asterisks) were
visualized by plotting them onto the corresponding segments of the known crystal structure of HXBc2 gp120 core (Kwong et al., 1998). The peptides
that reacted to antisera from animals immunized with the wild-type envelope are shown in (A). The upper portion of the panel shows ribbon diagram,
while the lower portion shows the surface map of gp120. The left-most images depict the view from the target cell membrane. The successive images
from the left to right show approximately 90° turn along the top–bottom axis. Thus, the third image from the left depicts the view from the orientation
of the viral membrane. The receptor-binding sites (CD4 and coreceptor) and the stems of the missing variable loops V1/V2 and V3 are indicated. Also
indicated are the amino- and carboxyl-termini of the gp120 core protein used to determine the crystal structure, and the residual carbohydrate
moieties (N-acetyl-D-glucosamine and fucose, shown in blue-green). The immunoreactive peptides are color coded as the following: peptides 12, 13,
and 15 (C1 region) in red; peptides 40 and 46 (C2 region) in blue and yellow, respectively; peptide 61 (C3 region) in green; and peptides 87/88 and
91 (C5 region) in cyan and magenta, respectively. Immunoreactive peptides to antisera from animals immunized with either V1/V2 or V3 are shown
in (B). Peptides that exhibited enhanced reactivity by the deletion of V1–2 (peptides 85 and 86) are shown in gold. Peptides that were enhanced by
the deletion of the V3 loop (peptide 48) or by either V1–2 or V3 loops (peptide 47) are shown in purple.
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lated (“immunosilent face”) or to areas where CD4 and
coreceptors bind (“neutralizing face”). Interestingly, many
of the immunoreactive peptides we identified overlapped
sequences that form alpha helix. Whether this is due to
possibilities that alpha helices are inherently immuno-
genic, or that they are easily detected by peptide ELISA,
or both, is not known.
Peptides that are immunogenic in V1–2 and V3
envelopes are shown in Fig. 5B. Peptides that exhibited
enhanced reactivity by V1–2 (peptides 85 and 86) were
positioned in the junction between the inner and the
outer domains (shown in gold). The peptides that were
enhanced by V3 (peptide 48), or by V1–2 and V3
(peptide 47), are located in the outer domain (in purple).
None of these peptides, however, mapped to the neu-
tralizing face of the protein.
DISCUSSION
In this study, we examined immunological properties
of wild-type and variable loop-deleted gp120s with an
ultimate goal of identifying an immunogen that can elicit
broadly reactive Nabs against HIV-1. The rationale be-
hind this vaccine strategy is based on an observation
that the removal of variable loops V1/V2 and V3 in-
creases affinity of Nabs directed against the CD4-bind-
ing domain, presumably due to enhanced exposure of
the epitope (Wyatt et al., 1993). Additionally, variable
loops V1/V2 (V2 in particular) are thought to mask the
coreceptor-binding site, which is transiently exposed
only after gp120 binds CD4 (Cao et al., 1997; Wyatt et al.,
1995). Disappointingly, the variable loop-deletion mutant
envelope constructs we generated did not elicit either
more potent or broadly cross-reactive Nab responses
compared to the wild-type envelope.
Immunogenicity of variable loop-deleted envelopes
has been evaluated in two other studies (Barnett et al.,
2001; Lu et al., 1998). In the study by Lu et al. (1998),
immunogenicity of three different wild-type and V1/V2/
V3-deleted envelope constructs (gp120, gp140, and
gp160) was compared in rabbits using DNA vaccine
approach. Although the variable loop-deleted antigens
were better than the wild-type in eliciting antibodies that
bind mutant gp120, the antibodies elicited by the wild-
type antigens were better in binding the wild-type gp120.
More importantly, only the wild-type envelopes (gp120
and gp140) were able to elicit Nabs. These results sug-
gested that while the removal of the variable loops gen-
erated or exposed new immunogenic determinants, they
are not present or accessible in the wild-type protein.
Consequently, antibodies to these determinants did not
neutralize the virus. Barnett et al. (2001) examined immu-
nogenicity of HIV-1SF162-derived gp140 construct with de-
letion of the V2 loop only (30 amino acids), in rabbits
(DNA) and in rhesus macaques (DNA prime-protein
boost). They have demonstrated that V2 loop-deleted
immunogen, compared to the wild-type envelope, elic-
ited similar (rabbit) or lower (macaque) ELISA antibody
titer against gp140. However, the mutant envelope elic-
ited slightly higher Nab titer against the wild-type virus
and modestly broader, albeit weak, neutralizing activity
against a limited number of heterologous primary HIV-1
isolates. Despite some success, the authors of the study
concluded that additional modifications must be intro-
duced to elicit Nabs with increased potency and breadth.
The moderate success reported by Barnett et al.
(2001), in contrast to our study, and that of Lu et al. (1998),
might be attributed to the use of a mutant envelope
construct that contains much smaller deletion, which
does not abrogate infectivity of the virus containing the
mutation. Although our V3- and V4-loop deletions were
as small as their V2 loop deletion (33 and 28 amino
acids, respectively), deletions of the V3 and V4 loops
might be more deleterious than that of the V2 loop. That
is, both V3- and V4-loop deleted gp160 constructs exhib-
ited a significant defect in gp160 processing, whereas
processing of the V1/V2-deleted construct was largely
unaffected (Fig. 2). Furthermore, while viable HIV-1 and
SIV variants with V1/V2 or V2 loop deletions have been
isolated (Cao et al., 1997; Johnson et al., 2002; Stamata-
tos and Cheng-Mayer, 1998), viable virus containing ei-
ther V3 or V4 loop deletions, to our knowledge, has never
been observed. In this regard, the use of envelope con-
structs with less drastic deletion of the variable loops
might result in a better outcome. In our study, we re-
placed variable loops V1/V2, V3, and V4 with dipeptides
(GS, EF, and PG, respectively). In the study reported by
Lu et al. (1998), trimeric peptide (GAG) replaced the
V1/V2 and V3 loops. One of the remaining challenges for
successfully using variable loop-deleted envelopes as
immunogens might be generating deletion mutants that
maintain functionality of the envelope.
To gain insights as to why the variable loop-deleted
envelope constructs failed to elicit enhanced Nab re-
sponse, immunogenic epitope analysis was performed
using peptide ELISA (Figs. 4 and 5). For HIV-1DH12, a dual
tropic clade B primary isolate that can utilize either
CXCR4 or CCR5 (X4R5) (Cho et al., 1998), the single most
immunogenic determinant was the variable loops V1/V2.
This is consistent with our previous observation that
immune serum from a chimpanzee infected with
HIV-1DH12 could efficiently immunoprecipitate DH12
gp120 and a chimeric gp120 that contained the DH12
V1/V2 region in the background of HIV-1AD8 envelope;
AD8 gp120 or chimeric gp120s that contained the V3, V4,
or V5 regions of DH12 were not immunoprecipitated
efficiently (Cho et al., 2000). The V1/V2 region, together
with the conserved regions C1 and C5, accounted for
75% (12 of 16) of all immunoreactive peptides identified in
gp120. Other immunogenic peptides included two in the
C2 region, one in the V3 loop, and one in the junction
between V3 and C3. In contrast, much of the C3, V4, C4,
132 KIM ET AL.
and V5 regions were nonimmunogenic. These regions
were also nonimmunogenic in the variable loop-deleted
mutant envelopes, with the exception of the V5 region in
the V1/V2-deleted envelope construct. Other than the V2
and V3 loops, conserved, discontinuous epitopes de-
rived largely from the sequences within the C3 and C4
regions, which overlap the CD4 binding site, are the
major targets of Nabs (Cordonnier et al., 1989; Ho et al.,
1991; Kang et al., 1991; Lasky et al., 1987; Olshevsky et al.,
1990; Steimer et al., 1991; Thali et al., 1991, 1992; Tilley et
al., 1991). The C1 and C5 regions, although highly immu-
nogenic, are not exposed in the oligomeric structure of
envelope on the virion surface and do not serve as
targets for Nabs (Helseth et al., 1991; Kowalski et al.,
1987; Kwong et al., 1998; Moore et al., 1994; Moore and
Sodroski, 1996; Wyatt et al., 1998). Together, these factors
might explain why the variable loop-deleted mutant en-
velopes (V1/V2 and/or V3 in particular) were less able
or unable to elicit Nabs against DH12, and why none of
the envelope antigens (including the wild-type) could
elicit Nabs against heterologous HIV-1 isolates that we
tested.
VanCott et al. (1999) have evaluated immunogenic
epitopes in gp120 of HIV-1CM235 (R5 clade E primary iso-
late) and HIV-1SF2 (X4 clade B T cell line adapted (TCLA)
isolate). In their study, antisera from baboons immunized
with recombinant gp120 of either CM235 or SF2 were
used to probe 12-mer peptides (overlapping by eight
amino acids). In their study, immunogenic peptides were
defined as being reactive to at least 40% of sera from
immunized animals. Some striking similarities and differ-
ences were observed when the immunogenic epitopes
of DH12 strain were compared to those of CM235 and
SF2. For all three isolates, the C1, V1/V2, C2, V3, and C5
regions were quite immunogenic. However, a major dif-
ference was seen for the C3, V4, and C4 regions. In
contrast to both CM235 and DH12, in which no immuno-
genic epitopes were identified, approximately 38% (14 of
38) of all immunoreactive peptides were identified in
these regions for SF2. This difference in immunogenicity
most likely reflects intrinsic differences in the structure of
TCLA X4 gp120 compared to that of R5 or X4R5 primary
isolates, which is responsible for the increased sensitiv-
ity of TCLA isolates to neutralization by soluble CD4 or
Nabs (Beddows et al., 1998; Golding et al., 1994; Mascola
et al., 1996; Matthews, 1994; Moore and Ho, 1995; Moore
et al., 1992; Sullivan et al., 1995). Among the 16 peptides
that were immunoreactive for DH12, 12 corresponding
peptides were also reactive for SF2 (peptides 6, 12, 13,
15, 27, 30, 46, 56, 61, 87, 88, and 91), while only 8 were
reactive for CM235 (peptides 15, 27, 30, 40, 46, 56, 87, and
88). Whether the closer similarity between DH12 and SF2
is due to the fact that both DH12 and SF2, but not CM235,
utilize CXCR4 coreceptor is under speculation. The
amino acid segments that were immunoreactive to all
three isolates were found in the C1, V1/V2, C2, V3, and C5
regions (peptides 15, 27, 30, 56, 87, and 88).
In our study and the one by VanCott et al. (1999),
animals were immunized with whole envelope proteins,
and the immunogenic epitopes were identified by prob-
ing a series of peptides with the immune sera. In the
study done by Vahlne et al. (1991), macaques were indi-
vidually immunized with 1 of 40 different peptides of
variable lengths (17–29 amino acids) derived from
HIV-1IIIB and the antisera against the peptides were used
to probe whole gp120. Although all except one peptide in
the C5 region elicited peptide-specific antibodies, anti-
sera against only 12 of them reacted with gp120. Many of
these peptides were derived from the C1 region (five
peptides). Surprisingly, 8 of 12 immunoreactive peptides
identified by Vahlne et al. matched those peptides found
to be immunogenic in our study (peptides 6, 12, 13, 15,
24, 56, 87, and 88). Although there is a general consen-
sus of immunogenic epitopes of gp120, one cautionary
note is that the immunogenic epitopes could vary de-
pending on the antigen, quality of antigen, immunization
modality, adjuvant used, and the genetic makeup of an-
imals or person being immunized. Additional work is
needed to identify factors important for determining hu-
moral immune response against HIV-1 envelope glyco
protein.
In this study, we have shown that immunogenic deter-
minants of gp120 mapped primarily to the inner domain
of the protein and to the variable loops, in agreement
with previously published studies (for reviews, see Sat-
tentau et al., 1999; Wyatt et al., 1998). The antibodies
against these regions have either no or only strain-
specific neutralizing activity. We were able to alter im-
mune responses by removing the variable loops. How-
ever, the newly targeted epitopes were not on the exter-
nal surface, which includes highly glycosylated
immunosilent face and the receptor-binding neutraliza-
tion face. Our results clearly indicate that obtaining
broadly reactive Nabs might not be achieved by simply
deleting the variable loops of gp120. However, the ob-
servation that the immune responses could be redi-
rected by changing the protein composition allows us to
explore alternative strategies for modifying the antigenic
properties of HIV-1 envelope. One possible approach
might be combining variable loop-deletion with the re-
moval of glycosylation sites. Another approach might be
eliminating immunodominant epitopes that do not con-
tribute to eliciting Nabs. For example, removing (or sup-
pressing immunogenicity of) the C1 and C5 regions of
gp120, in addition to V1/V2 deletion, might improve im-
munogenicity of the C3 and C4 regions. Of course, the
challenge would be engineering such a protein without
destroying proper conformation of the authentic neutral-
ization epitopes.
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MATERIALS AND METHODS
Plasmids and recombinant vaccinia viruses
Recombinant vaccinia viruses that express wild-type
HIV-1DH12 gp160 (vvDHenv) and histidine-tagged gp120
(vDHgp120H), and the plasmids used to generate those
recombinants (pNVV-DHenv and pTM-DHgp120H, re-
spectively), have previously been described (Cho et al.,
2000, 2001; Lee et al., 2000). Variable loops (V1–2, V3,
and V4) were removed from pTM-DHgp120H (pTM-
DHgp120H-V1–2, -V3, and V4, respectively) by a
strategy using PCR amplification of two fragments of the
envelope gene (upstream and downstream with respect
to each variable loop), followed by a three-fragment liga-
tion reaction (Fig. 1). For pTM-DHgp120HV1–2 con-
struct, the upstream fragment was amplified using F-env
primer and V1–2(U) primer, while the downstream frag-
ment was amplified using V1–2(D) primer and R-env
primer. The upstream fragment was digested with PstI
and BamHI and the downstream fragment was digested
with BamHI and XhoI. These two fragments were subse-
quently ligated to the vector fragment, which was gen-
erated by digesting with PstI and XhoI. Similarly, the
pTM-DHgp120H-V3 and -V4 constructs were gener-
ated using EcoRI and XbaI, respectively. To generate
pTM-DHgp120HV1–3, BglII fragment (nts 817-1376)
containing the V3 region from pTM-DHgp120HV3 was
transferred to the corresponding region of pTM-
DHgp120HV1–2. To generate plasmids encoding vari-
able loop-deleted gp160s, the fragments from the gp120
constructs carrying each of the deleted variable loops
(NsiI and StuI for V1–2 and BglII-BglII for V3 or V4)
were inserted into the corresponding regions in pNVV-
DHenv to generate pNVV-DHenv-V1–2, -V3, and -V4,
respectively. pNVV-DHenvV1–3 was constructed by
transferring the BglII fragment of pTM-DHgp120HV3
into pNVV-DHenvV1–2. pTM- and pNVV-vectors encod-
ing variable loop-deleted gp120s and gp160s, respec-
tively, were used to generate recombinant vaccinia vi-
ruses as previously described (Cho et al., 1994; Mackett
et al., 1985). To generate a recombinant vaccinia virus
expressing SIV gag-pol, a 4.9-kb StuI (nt 682)-BstBI
(5587) fragment from SHIV-DH12 (Shibata et al., 1997)
containing SIVmac239 gag-pol gene was cloned into a
vaccinia-recombinant vector pNVV-3 (Cho et al., 2000) to
produce pNVV-SIVgagpol. The resulting plasmid was
used to generate the vaccinia virus. All of the recombi-
nant vaccinia viruses employed in this study have been
derived from WR strain of vaccinia virus.
Protein expression and preparation of vaccines
In general, propagation of the recombinant vaccinia
viruses and expression analyses of viral gene products
were done in HeLa cells. To express histidine-tagged
gp120 (gp120H), the cells were coinfected with the vac-
cinia viruses encoding gp120 and vTF7-3, a recombinant
vaccinia virus expressing T7 RNA polymerase (Fuerst et
al., 1986). HeLa cell cultivation, virus infection, cell-lysate
preparation, and gp120H purification using Ni-affinity col-
umn were done as previously described (Cho et al., 2001;
Lee et al., 2000). Compare to the wild-type gp120H,
variable loop-deleted gp120H proteins exhibited slightly
weaker affinity to the Ni-NTA column. To prevent protein
loss during purification, washing buffer containing lower
salt concentration was used (50 mM sodium phosphate,
pH 8.0, 250 mM NaCl, rather than 500 mM NaCl). The
purified gp120H proteins were dialyzed against phos-
phate-buffered saline (PBS) at 4°C for 16–24 h and sub-
sequently concentrated to approximately 1 mg/ml using
a 10,000 Da cutoff centrifugal ultrafilter unit (Millipore). To
avoid eliciting immune responses to human protein con-
taminants in the recombinant vaccinia virus prepara-
tions, vaccinia viruses used for immunization were prop-
agated in Mus dunni cells rather than HeLa. Viruses
were purified on a linear sucrose gradient, resuspended
in PBS, and titered as previously described (Mackett et
al., 1985). SIV gag was expressed in Spodoptera frugi-
perda Sf9 insect cells using a recombinant baculovirus,
which was kindly provided by Dr. Richard Compans
(Yamshchikov et al., 1995). The purification procedure for
SIV gag will be described elsewhere (unpublished data).
HIV-1 envelope proteins were detected by Western blot
using rabbit anti-gp160 antiserum and chemilumines-
cence detection system as previously described (Lee et
al., 2000).
Immunization
Eight-week-old BALB/c mice were housed in a bio-
safety level 2 facility and maintained in accordance with
American Association for Accreditation of Laboratory An-
imal Care standards. Animals were immunized four
times intraperitoneally with indicated antigens (Table 1).
Each animal received a total of 1  107 plaque forming
units (PFU) of the recombinant vaccinia viruses in 0.5 ml
PBS per immunization. For the second and third immu-
nization, the animals were immunized with the vaccinia
viruses and 50 g recombinant gp120s in 0.5-ml volume.
For the control group immunized with SIV gag-pol, only
vaccinia virus was given. For the final immunization,
each animal received 50 g of either SIV gag or HIV-1
gp120 with 50 g QS-21 as an adjuvant (kindly provided
by Dr. Charlotte Kensil, Aquila Biopharmaceuticals). The
animals were bled from tail either prior to (prebleed) or
9–11 days after immunization.
ELISA
ELISA using recombinant HIV-1DH12 gp120 as an anti-
gen was performed as previously described (Cho et al.,
2001). HIV-1DH12 gp120 peptides (PepSets) used to map
linear immunogenic epitopes were purchased from Chi-
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ron Technologies (Raleigh, NC). Peptides were dissolved
in PBS containing either 5 or 10% DMSO. Nunc Maxisorp
96-well plates were coated with the peptides (4 mol per
well) in 50 l coating buffer (15 mM Na2CO3, 35 mM
NaHCO3, 3 mM NaN3, pH 9.6) for 1 h at 37°C. The
coating mixture was replaced with 100 l of blocking
buffer (2.5% skimmed milk, 25% fetal bovine serum, in
PBS) and incubated for 1 h at 37°C. Plates were washed
twice with PBS-T (PBS containing 0.1% Tween 20). Mouse
antiserum (pooled for each vaccine group) in 50 l of
blocking buffer (1:100 dilution) was added to each well
and incubated for 1 h at 37°C. Plates were washed three
times with PBS-T and 100 l of horseradish peroxidase
conjugated goat anti-mouse antibodies were added
(Pierce; 1:5000 dilution in the blocking buffer) for 1 h at
37°C. Plates were washed again three times with PBS-T,
and 100 l of TMB substrate was added. Reaction was
stopped after 10 min with 50 l of 2 N H2SO4 and the
absorbency was measured at 450 nm using 96-well plate
spectrophotometer (Bio-Tek Instruments).
Neutralization assay
Neutralization assays were performed using MuLV
pseudotyped with gp140 of indicated HIV-1 isolates as
previously described (Kim et al., 2001; Schnierle et al.,
1997). Briefly, serially diluted heat-inactivated mice anti-
sera or monoclonal antibody IgG1b12 (Barbas et al.,
1992; Burton et al., 1991, 1994; Roben et al., 1994) were
incubated with pseudoviruses for 1 h at 37°C. Twenty
microliters of the mixture containing approximately 50
infectious particles was subsequently added to HOS-
CD4-CCR5 or -CXCR4 cells (Cheng-Mayer et al., 1997;
Deng et al., 1996) in 96-well plates in duplicate. Cells
were incubated at 37°C in 5% CO2 incubator for 2 days
and stained for -gal activity. Neutralization titer is re-
ported as serum dilution factor, or antibody concentra-
tion, at which zero or one to five blue cells are observed
in both duplicate wells (for 100 or 90% neutralization,
respectively).
Three-dimensional visualization of immunogenic
epitopes on gp120
Immunoreactive peptides were visualized using
Chemscape Chime program, which runs on Netscape. A
modified version of subroutine Quizzer was used to iden-
tify and color specific amino acids. The coordinate for
gp120 crystal structure (1GC1) was downloaded from
Protein Data Bank.
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